DOACs in heparin-induced thrombocytopenia
Studies of direct oral anticoagulants for the treatment of heparin-induced thrombocytopenia.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 0, 0, 3, 0, 0.
All papers from the last 12 months
20 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Anticoagulation in Mechanical Circulatory Support: Contemporary Challenges and Future Directions in Cardiovascular PharmacotherapyCardiol Ther2026 Oct 16PMID 42886412Review
- Direct Oral Anticoagulants as Primary or Secondary Treatment for Heparin-Induced Thrombocytopenia (HIT) and Associated Thromboembolism (HITT)-A Meta-AnalysisEur J Haematol2026 OctPMID 42306844Meta-analysisSystematic review
- Anticoagulants, Their Laboratory Monitoring, and ReversalHematol Rep2026 Sep 20PMID 42776833Review
- Things We Do for No Reason™: Routine use of unfractionated heparin for initial anticoagulation in venous thromboembolismJ Hosp Med2026 SepPMID 42007523Review
- Automated DNA-Encoded Library Synthesis and Activity-Based Screening at the Attomole ScaleJ Med Chem2026 Aug 13PMID 42482528
- Fondaparinux to treat cerebral venous sinus thrombosis complicated by heparin-induced thrombocytopenia during puerperium: A case report and literature reviewInt J Clin Pharmacol Ther2026 AugPMID 42112699Review
- Possible atypical heparin-induced thrombocytopenia presenting with splenic infarction despite preserved platelet counts after cardiac surgery - a case reportFront Med (Lausanne)2026PMID 42591251
- Adrenal hemorrhage requiring apixaban reversal in the setting of active deep vein thrombosis and heparin-induced thrombocytopenia: A case reportAm J Health Syst Pharm2026 Jul 8PMID 41776964
- The Year in Coagulation and Transfusion: Selected HighlightsJ Cardiothorac Vasc Anesth2026 JulPMID 41876318Review
- Case Report: Heparin resistance as the harbinger of heparin-induced thrombocytopenia in acute pulmonary embolismFront Med (Lausanne)2026PMID 42396168
More hematology trends
All specialties →Myelofibrosis treatment
JAK inhibitors and newer drugs in myelofibrosis.
Key point: Ruxolitinib-based combination regimens showed improved spleen and symptom responses with acceptable safety, with efficacy significantly influenced by prior JAK inhibitor exposure.
Post-transplant cyclophosphamide
Cyclophosphamide after stem cell transplant to prevent graft-versus-host disease.
Key point: Post-transplant cyclophosphamide appears to reduce graft-versus-host disease without increasing relapse or mortality in matched related donor transplantation for acute leukemia.
Haemophilia
Haemophilia and its newer treatments, including gene therapy and non-factor drugs.
Targeted therapy in CLL
BTK and BCL2 inhibitors in chronic lymphocytic leukaemia.
Key point: In CLL/SLL, treatment selection is tailored based on age, genetic risk and comorbidities, prioritizing zanubrutinib, acalabrutinib and venetoclax-based regimens.
Paroxysmal nocturnal haemoglobinuria
PNH and new oral complement inhibitors.
Menin inhibitors in AML
Revumenib, ziftomenib and other menin inhibitors in acute leukaemia.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("heparin-induced thrombocytopenia"[tiab] OR HIT[tiab]) AND ("direct oral anticoagulant*"[tiab] OR DOAC*[tiab] OR rivaroxaban[tiab] OR apixaban[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.